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Mitochondrial fatty acid oxidation provides an impor-
tant energy source for cellular metabolism, and
decreased mitochondrial fatty acid oxidation has
been implicated in the pathogenesis of type 2 dia-
betes. Paradoxically, mice with an inherited defi-
ciency of the mitochondrial fatty acid oxidation
enzyme, very long-chain acyl-CoA dehydrogenase
(VLCAD), were protected from high-fat diet-induced
obesity and liver and muscle insulin resistance. This
was associated with reduced intracellular diacylgly-
cerol content and decreased activity of liver protein
kinase C3 and muscle protein kinase Cq. The
increased insulin sensitivity in the VLCAD/ mice
were protected from diet-induced obesity and insulin
resistance due to chronic activation of AMPK and
PPARa, resulting in increased fatty acid oxidation
and decreased intramyocellular and hepatocellular
diacylglycerol content.
INTRODUCTION
Mitochondrial dysfunction with impaired skeletal muscle oxida-
tive phosphorylation has been implicated in the pathogenesis
of insulin resistance and type 2 diabetes mellitus (T2DM) (Kelley
et al., 2002; Petersen et al., 2003; Mootha et al., 2003; Patti et al.,
2003; Petersen et al., 2004). Mitochondrial dysfunction resulting
from a deficiency of long-chain acyl-CoA dehydrogenase (LCAD)
caused fatty liver and hepatic insulin resistance in mice (Zhang
et al., 2007). A closely related enzyme of the same pathway,
very long-chain acyl-CoA dehydrogenase (VLCAD), is a mito-
chondrial membrane-associated enzyme that is upstream of
long-chain acyl-CoA dehydrogenase in the mitochondrial fatty
acid b-oxidation spiral. Previous studies in humans have found
that VLCAD deficiency resulted in reduced fatty acid oxidation
and was associated with fasting intolerance, Reye syndrome-
like disease, and cardiac and skeletal muscle disease (Cox402 Cell Metabolism 11, 402–411, May 5, 2010 ª2010 Elsevier Inc.et al., 2001). To further investigate the relationship between fatty
acid oxidation enzyme deficiency and insulin resistance, we per-
formed metabolic studies on VLCAD-deficient (VLCAD/) mice
after high-fat feeding. Surprisingly, we found that the VLCAD/
mice were resistant to high-fat diet-induced obesity and insulin
resistance with a mechanism related to activation of AMPK in
liver and skeletal muscle and a compensatory increase in fatty
acid oxidation.RESULTS
VLCAD/ Mice Are Resistant to High-Fat Diet-Induced
Obesity Due to Decreased Energy Intake and Decreased
Respiratory Quotient
Preliminary hyperinsulinemic-euglycemic clamp study of the
VLCAD/mice fed standard diet showed no difference in insulin
sensitivity compared to WT mice (Figure S1 available online). To
investigate why a major fatty acid oxidation enzyme deficiency
did not lead to insulin resistance, we subjected the VLCAD/
mice to a high-fat diet. Of interest, 2 weeks of ad lib feeding of
the high-fat diet caused a 40% increase in body weight in the
WT mice while only causing a 10% increase in body weight in
the VLCAD/ mice within the same period (Figure 1A, day 14).
Another 3 months of high-fat feeding led to further body weight
gains in both groups, with the WT gaining slightly more than
the VLCAD/ mice (Figure 1A, p < 0.05 from day 9 to day
100). Food intake measurements showed that VLCAD/ mice
had significantly less food intake than WT mice for the first
2 weeks of the feeding period (Figure 1B).
We next analyzed whole-body energy homeostasis in these
mice fed the same high-fat diet using indirect calorimetry. Of
interest, despite the absence of a key enzyme in mitochondrial
b-oxidation, VLCAD/ mice had a relatively higher percentage
of fatty acid oxidation compared to WT controls, reflected by
a 20%decrease in RQ (calculated from the area under the curves
of Figure 1C, p < 0.01). Overall energy expenditure was 15%
lower (calculated from the area under the curves of Figure 1D,
p < 0.05) in the VLCAD/ mice. Measurements of intestinal fat
absorption in VLCAD/ and WT mice demonstrated no differ-
ences in fat absorption between the two groups when fed the
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Figure 1. Body Weight and Food Intake during
High-Fat Feeding and Calorimetry Measurements
(A) VLCAD/ mice have significantly lower body weight
(p < 0.05) than WT mice when fed a high-fat diet ad lib
for 100 days.
(B) VLCAD/ mice have significantly lower food intake
(p < 0.05) as compared to WT mice fed a high-fat diet ad
lib for the first 2 weeks of feeding.
(C and D) VLCAD/ mice have (C) significantly lower RQ
(p < 0.001) and (D) lower energy expenditure (p < 0.02)
as compared to WT controls measured over 24 hr. RQ
and energy expenditure measurements were performed
on mice pair-fed high-fat diet for 3 months.
In both groups, n = 7. Values are mean ± SEM.
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VLCAD/ Mice Are Protected from Insulin Resistancesame high-fat diet (Table 1). Taken together, these data suggest
that the VLCAD/ mice are resistant to high-fat diet-induced
obesity due to decreased food intake. Because previous studies
with carnitine palmitoyltransferase-1 inhibition in the hypothal-
amus have implicated increased hypothalamic long-chain acyl-
CoA concentrations in reducing food intake (Obici et al., 2003),
we examined hypothalamic long-chain acyl-CoA concentrations
in high-fat-fed VLCAD/ and WT mice but found no differences
in long-chain acyl-CoA concentrations (Table 1).
Because there was a marked difference in body weight
between the two groups of mice after ad lib high-fat feeding,
which is known to affect insulin-stimulated glucose metabolism,
we subsequently studied VLCAD/ and WT mice after 3 weeks
of pair-feeding the high-fat diet. As expected, VLCAD/ mice
andWTmice pair-fed the high-fat diet had a similar body weight,
but VLCAD/ mice had a 36% decrease in whole-body fatCell Metabolism 1content (p < 0.01) as compared to WT control
mice (Table 1). Basal plasma concentrations of
glucose, insulin, triglyceride, b-hydroxybutyrate,
and cholesterol were similar in the two groups.
However, plasma fatty acid levels were 30%
higher in the VLCAD/ mice, consistent with
their inborn error of metabolism as compared
to the WT control mice. There were no differ-
ences in plasma concentrations of IL-6, TNFa,
or resistin between the two groups of mice
(Table 1). However, adiponectin and leptin
concentrations were both 40% lower in the
VLCAD/ mice compared to the WT controls.
VLCAD/ Mice Were Protected from
High-Fat Diet-Induced Insulin Resistance
To investigate the effect of VLCAD/ deficiency
on glucose metabolism, we performed hyperin-
sulinemic-euglycemic clamp studies on WT and
VLCAD/ mice pair-fed the high-fat diet for 3
weeks. Reduced food intake in the WT mice
(450 kcal/kg/d) due to pair-feeding, as
compared to their ad lib intake, did not protect
the mice from severe insulin resistance caused
by high-fat feeding (Figure 2A). In stark contrast,
VLCAD/ mice required a significantly higher
glucose infusion rate (Figure 2A) in order to
maintain euglycemia during the clamp, reflect-ing increased whole-body insulin sensitivity (Figure 2B). This
increased whole-body insulin responsiveness in the VLCAD/
mice could be attributed to both increased peripheral glucose
uptake (Figure 2B) and increased suppression of hepatic
glucose production during the clamp (Figure 2C). Consistent
with these data, VLCAD/ mice also had significantly higher
insulin-stimulated 2-deoxy glucose uptake in skeletal muscle
(Figure 2D) during the clamp compared to the WT mice.
Consistent with the increased insulin suppression of hepatic
glucose production in liver and insulin-stimulated glucose
uptake in muscle, insulin-stimulated Akt2 activities in the liver
and muscle of the VLCAD/ mice were increased by 50% and
120%, respectively, compared to the WT controls (Figures 2E
and 2F). These data suggest that the VLCAD/ mice are pro-
tected from high-fat diet-induced insulin resistance both in liver
and in skeletal muscle. This was further supported by glucose1, 402–411, May 5, 2010 ª2010 Elsevier Inc. 403
Table 1. Metabolic Profile in Plasma of the WT and VLCAD/
Mice Pair-Fed High-Fat Diet for 3 Weeks
WT VLCAD/
Body weight (g) 28.3 ± 1.4 29.2 ± 0.5
Fat mass (g) 4.7 ± 0.7 3.0 ± 0.2a
Glucose (mg/dl) 172 ± 7.3 168 ± 7.4
Insulin (pM) 167 ± 33 137 ± 16
Adiponectin (mg/ml) 7.9 ± 0.7 4.9 ± 0.5a
Leptin (ng/ml) 7.1 ± 1.3 3.8 ± 0.5a
IL-6 (pg/ml) 17 ± 3.6 28 ± 4.4
TNFa (pg/ml) 6.8 ± 1.6 9.3 ± 1.1
Resistin (ng/ml) 2.7 ± 0.4 2.1 ± 0.1
Triglyceride (mg/dl) 38 ± 2.5 41 ± 2.5
NEFA (mM) 0.62 ± 0.03 0.81 ± 0.03a
b-hydroxybutyrate (mM) 0.33 ± 0.07 0.23 ± 0.04
Total cholesterol (mg/dl) 64 ± 4.9 77 ± 7.6
Fat absorption (%) 99.0 ± 0.3 99.5 ± 0.1
Hypothalamus Acyl-CoA (nmol/g) 48.2 ± 3.8 51.7 ± 6.1
Fat mass and lean mass were obtained from awake mice with a Bruker
Mini-Spec Analyzer. Plasma glucose and insulin were basal values before
the hyperinsulinemic-euglycemic clamp. Data represent mean ± SEM of
nine mice per group.
a p < 0.01 compared with wild-type controls.
Cell Metabolism
VLCAD/ Mice Are Protected from Insulin Resistancetolerance testing, with significantly lower plasma glucose levels
(Figure 2G) and a trend of lower plasma insulin levels measured
during the test (Figure 2H).
Liver Protein Kinase C3 and Muscle Protein Kinase Cq
Activity Are Decreased in VLCAD/ Mice along with
Reduced Intracellular Diacylglycerol Content
To determine whether decreased activation of protein kinase C3
in liver and protein kinase Cq in skeletal muscle played a role in
protecting VLCAD/ from fat-induced insulin resistance, we
next measured protein kinase C3 and protein kinase Cq activity
in these tissues, as reflected by the membrane-to-cytosol ratio
of these proteins. Consistent with this hypothesis, we found
that protein kinase C3 and protein kinase Cq activity were
reduced by 35% and 50%, respectively, in the VLCAD/ mice
compared to the WT mice (Figure 3A). Diacylglycerol (DAG) is
a known activator of the novel PKCs, and VLCAD/ mice had
less intracellular DAG and triglyceride (TG) content compared
to the WT mice (Figures 3B and 3C). Acyl-CoA concentrations
were significantly higher (p < 0.01 [liver] and p < 0.05 [muscle])
in the VLCAD/ mice as compared to the WT mice (Figure 3D);
however, ceramide, another putative mediator of fat-induced
insulin resistance, was not different in either liver or skeletal
muscle in the two groups (Figure 3E).
AMPK Was Activated in VLCAD/ Mice Fed a High-Fat
Diet
We found a 220% increase in liver and a 100% increase in
muscle in AMPK activity in the VLCAD/ mice compared to
WT controls (Figure 4A). We hypothesized that AMPK activation
due to excess long-chain fatty acids in these tissues (Clark et al.,
2004; Za’tara et al., 2008) might explain the increased AMPK404 Cell Metabolism 11, 402–411, May 5, 2010 ª2010 Elsevier Inc.activity and serve as a compensatory mechanism to increase
fat oxidation with a reduction in substrate available for DAG
synthesis. The AMPK downstream target, acetyl-CoA carbox-
ylase (ACC), was found to be phosphorylated 3- and 4-fold
higher in the liver and muscle of the VLCAD/ mice (Figures
4C and 4D). Consistent with increased ACC phosphorylation,
which leads to decreased ACC activity, liver malonyl-CoA
content was also found to be lower in the VLCAD/ mice
(Figure 3F). In contrast, there were no differences in liver or
muscle AMPK activity in the LCAD-deficient mice (Figure 4B).
In vitro measurements with freshly isolated liver, muscle, and
brown adipose tissue (BAT) showed significantly higher rates
of fatty acid oxidation in the VLCAD/ mice compared to WT
control mice (Figure 4E). These data suggest that increased
long-chain fatty acyl-CoAs (Figure 3G) in the VLCAD/ mice
were able to activate AMPK and compensate partially for
the loss of function in fatty acid oxidation while significantly
increasing insulin sensitivity in these mice. In contrast, however,
the deficiency of fatty acid oxidation in the LCAD/mice did not
lead to activation of AMPK (Figure 4B) in liver or muscle; thus,
there was no compensation in fatty acid oxidation, resulting in
exacerbated hepatic insulin resistance in these mice (Zhang
et al., 2007). The predominant substrates that build up in LCAD
deficiency are the medium-chain length C14:1 acyl-CoA and
C14:1 acylcarnitine (Kurtz et al., 1998; Zhang et al., 2007).
We then measured acylcarnitines in plasma, muscle, and liver
of these mice because acylcarnitine measurement is an impor-
tant clinical indicator for disorders in fatty acid oxidation. Plasma
long-chain acylcarnitines (C14 to C18) were slightly increased;
however, liver and muscle long-chain acylcarnitines were not
statistically different (Figure S2).
In order to further understand the metabolic phenotype in
thesemice, we performed quantitative RT-PCR tomeasure liver,
muscle, and BAT expression of genes involved in fatty acid
metabolism in the WT and VLCAD/ mice pair-fed high-fat
diet. We found a dramatic compensatory increase in muscle
and BAT gene expression of PPARa and LCAD in the VLCAD/
mouse group (Table 2). There was no difference in liver gene
expression of PPARa and LCAD, probably because these genes
inWTmice were also upregulated in liver due to high-fat feeding.
In addition, there was no difference in gene expression of
PGC1a, PPARd, and AOX in liver, muscle, or BAT. Of interest,
muscle PGC1b and SREBP1 gene expression were downregu-
lated significantly, indicating a strong transcriptional mechanism
that reduces lipogenesis in skeletal muscle in the VLCAD/
mice. In contrast, PGC1b and SREBP1 gene expression in liver
and BAT were not different. In addition, there was a 23%
increase in UCP1 gene expression in BAT of the VLCAD/mice.
DISCUSSION
Characteristics of VLCAD Deficiency in Humans
and Mice
VLCAD deficiency is a potentially fatal disease, which frequently
appears in the neonatal period presenting with hypoketotic/
hypoglycemia, fatty liver, and cardiac disease (Roe and Ding,
2001). In direct side-by-side comparisons of the LCAD- and
VLCAD-deficient mice (Cox et al., 2001), we found many similar-
ities with the other VLCAD/ model (Exil et al., 2003); however,
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Figure 2. VLCAD/Mice Are Resistant to High-Fat
Diet-Induced Insulin Resistance
(A–D) VLCAD/ mice are resistant to high-fat diet-
induced insulin resistance, as demonstrated by (A) a signif-
icantly higher glucose infusion rate, (B) significantly higher
whole-body glucose uptake (Rd), (C) significantly higher
insulin-mediated suppression of hepatic glucose produc-
tion (HGP), and (D) a significantly higher skeletal muscle
glucose uptake as compared to WT controls pair-fed
high-fat diet.
(E–H) The downstream effects include significantly
increased Akt2 activity in the liver (E) and muscle (F) of
VLCAD/ mice. VLCAD/ mice also had improved
glucose tolerance during IPGTT, as shown by a signifi-
cantly lower glucose curve (G) as compared to WT, while
the insulin curve was also trending lower (H).
*p < 0.05; **p < 0.01. In both groups, n = 7; both groups
were pair-fed the high-fat diet. Values are mean ± SEM.
Cell Metabolism
VLCAD/ Mice Are Protected from Insulin Resistancewe also found that the VLCAD-deficient phenotype related to
fatty acid oxidation deficiency is distinctly much milder than
the LCAD-deficient mice. This is further borne out in a recent
study (Cox et al., 2009) that demonstrated a profound cardiac
hypertrophy in the LCAD/ males, whereas the VLCAD/
males had a very mild hypertrophy (Cox et al., 2009). As
described previously, the LCAD-deficient mouse model (Kurtz
et al., 1998) is an excellent model of fatty acid oxidation defi-
ciency for studying human VLCAD deficiency, as it has markedly
elevated C14:1 acylcarnitine, the hallmark acylcarnitine signature
in human VLCAD deficiency, whereas the VLCADmousemodels
demonstrated a predominantly increased concentration of C16
and C18 acylcarnitines (Cox et al., 2001; Spiekerkoetter et al.,
2004, 2005), which are the acylcarnitines found at lower concen-
trations in WT mice. Furthermore, at least regarding the VLCAD-
deficient model (Cox et al., 2001) used in the present studies and
in the previous studies, when fed a standard rodent diet, the
heart, liver, and skeletal muscle had a normal level of palmitate
oxidation despite there being no detectable VLCAD mRNA or
protein; thus, it appears that mouse LCAD activity for the most
part compensates for VLCAD deficiency.Cell Metabolism 1Insulin Sensitivity and Resistance
to High-Fat Diet-Induced Obesity
in VLCAD/ Mice
VLCAD/ mice had better glucose tolerance in
response to a glucose tolerance test and were
protected fromdeveloping high-fat diet-induced
insulin resistance as found in the WT control
group. Of interest, even though plasma fatty
acids were higher in the VLCAD/ mice, as is
characteristic of their inherited enzyme defi-
ciency, they were more insulin sensitive than
were the WT controls, thus disassociating
insulin sensitivity fromplasma fatty acid concen-
trations.
To investigate whether protection from diet-
induced obesity in the VLCAD/ mice was
due to downstream effects of VLCAD deficiency
and hypothalamic control of feeding behavior
due to increased long-chain acyl-CoAs, assuggested by Obici and colleagues (Obici et al., 2003), we
measured acyl-CoAs in the hypothalamus and found no signifi-
cant differences between the genotypes. Furthermore, we found
no differences in digestive fat absorption. We also evaluated fat
utilization and energy expenditure. Surprisingly, we found a
higher percentage of fat oxidation, as reflected in the lower respi-
ratory quotient (RQ) values in the VLCAD/ mice as compared
to the WT controls.
VLCAD/ mice were resistant to developing whole-body
insulin resistance, as reflected by a higher glucose infusion
rate required to maintain euglycemia during the hyperinsuline-
mic-euglycemic clamp compared to the WT control mice. This
increased whole-body insulin responsiveness could be attrib-
uted to both increased insulin-stimulated skeletal muscle
glucose uptake and increased insulin-stimulated suppression
of hepatic glucose production in the VLCAD/ mice compared
to the pair-fed WT control mice. This increased insulin action
in liver and muscle could, in turn, be attributed to increased
activation of Akt2 in both of these tissues. The increased insulin
sensitivity was commensurate with decreased PKC3 and PKCq
activity in liver and skeletal muscle, respectively, associated1, 402–411, May 5, 2010 ª2010 Elsevier Inc. 405
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Figure 3. nPKC and Fatty Acid Metabolite
Measurements in Liver and Skeletal Muscle
(A) Protein kinase C3 or qmembrane translocation (activa-
tion) in liver and muscle of VLCAD/ mice were signifi-
cantly decreased as compared to WT controls.
(B and C) (B) Diacylglycerol (DAG) and (C) triglyceride (TG)
concentrations in liver were significantly lower in the
VLCAD/ mice.
(D) VLCAD/ mice had significantly higher total acyl-CoA
concentrations in liver (p < 0.01) and muscle.
(E) There were no significant differences in the liver cera-
mide concentrations.
(F) Liver malonyl-CoA was significantly lower in VLCAD/
mice.
(G) Liver acyl-CoA profile.
Open bars are WT, and black-filled bars indicate
VLCAD/ mice. *p < 0.05; **p < 0.01. In both groups,
n = 7; both groups were pair-fed the high-fat diet. Values
are mean ± SEM.
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VLCAD/ Mice Are Protected from Insulin Resistancewith decreased liver and muscle DAG and triglyceride concen-
trations in the VLCAD/ mice. Increases in tissue ceramide
content have been implicated in fat-induced insulin resistance
(Holland et al., 2007); however, in contrast to the increase in liver
and muscle DAG concentrations of insulin-resistant WT mice,
there were no differences in liver or skeletal muscle ceramide
concentrations between the VLCAD/ and WT mice.
Activation of AMPK in VLCAD/ Mice
We found a significant elevation in AMPK activity in both liver and
muscle of the VLCAD/mice as compared to WT control mice.
We hypothesized that, in mouse VLCAD deficiency, AMPK is
activated by elevated long-chain fatty acids (Table 1), as previ-
ously described (Clark et al., 2004; Za’tara et al., 2008). The
net effect of increased AMPK activity was increased phosphor-
ylation and inactivation of acetyl-CoA carboxylase in both liver
and muscle, and this resulted in a significant reduction in
malonyl-CoA in liver and a similar trend in muscle (data not
shown). The resulting change in fat metabolism would be
increased fatty acid oxidation (Figure 4E) via LCAD activity as
an alternative step to the deficient VLCAD step, resulting in
a net reduction of DAG, which has been implicated in the patho-406 Cell Metabolism 11, 402–411, May 5, 2010 ª2010 Elsevier Inc.genesis of muscle and liver insulin resistance
(Yu et al., 2002; Samuel et al., 2004).
Regulation of Metabolic Gene
Transcription in the VLCAD/ Mice
Previous studies have shown compensatory
upregulation of PPARa activity on its target
genes in response to a deficiency of the peroxi-
somal fatty acid oxidation enzyme acyl-CoA
oxidase (AOX) (Fan et al., 1998). Likewise, we
found significant increased expression of genes
in the mitochondrial fatty acid oxidation path-
way in the VLCAD/ mice, including genes for
PPARa and LCAD in both skeletal muscle and
BAT (Table 2). There were no differences in
gene expression of PPARd in liver, muscle, or
BAT in the VLCAD/ mice compared to the
WT mice, suggesting that PPARa-activated mitochondrial fatty
acid oxidation in muscle and BAT of the VLCAD/ mice is
a compensatory mechanism to increase energy production in
these tissues. In addition, we found an 25% increase in
UCP1 and peroxisomal AOX gene expression in BAT of the
VLCAD/mice, which would also promote increased fat oxida-
tion and energy dissipation.
In summary, we found that VLCAD/ mice, when challenged
by a high-fat diet, were significantly resistant to developing
insulin resistance as compared with WT control mice fed the
same diet. The pivotal changes that likely explain these results
include a significantly increased rate of fatty acid oxidation due
to both increased PPARa stimulation of peroxisomal fatty acid
oxidation gene expression and increased AMPK activity in liver
and muscle that would reduce malonyl-CoA suppression of fatty
acid oxidation, as well as reduce substrate for endogenous fatty
acid synthesis. The net result was significantly reduced DAG
concentrations in liver and skeletal muscle commensurate with
reduced PKC3 and PKCq activity, respectively, which have
been shown to cause insulin resistance in these tissues (Griffin
et al., 1999; Yu et al., 2002; Samuel et al., 2004; Neschen
et al., 2005; Savage et al., 2006; Samuel et al., 2007) (Figure 5).
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Figure 4. AMPK Activity and Phospho-Acetyl-CoA
Carboxylase
(A and B) AMPK activity is significantly elevated in (A)
VLCAD/ liver and skeletal muscle, but not in (B)
LCAD/ liver and skeletal muscle.
(C and D) VLCAD/ mice have significantly increased
phosphorylated (inactivated form) ACC in both (C) liver
and (D) skeletal muscle.
(E) Fatty acid oxidation is significantly increased in
VLCAD/ mouse liver, BAT, and skeletal muscle.
*p < 0.05; ***p < 0.001. In all groups, n = 7. Values are
mean ± SEM.
Cell Metabolism
VLCAD/ Mice Are Protected from Insulin ResistanceTaken together, these studies support the hypothesis that fat-
induced insulin resistance is due to an imbalance of fatty acid
delivery/synthesis versus mitochondrial/peroxisomal fatty acid
oxidation and that reductions in specific steps, such as VLCAD,
mitochondrial fatty acid oxidation as observed in the VLCAD/
mice, and other mouse models (Wredenberg et al., 2006; Pospi-
silik et al., 2007), can promote increased insulin-stimulated
glucose metabolism by compensatory mechanisms involving
activation of AMPK and PPARa.EXPERIMENTAL PROCEDURES
Animals
Male VLCAD/, LCAD/, and WT controls were produced as described
previously (Cox et al., 2001) and studied at 12 weeks of age. VLCAD/
andWTmice had a 129S6/B6 mixed background. Animals were housed under
controlled temperature (23C) and lighting (12 hr of light and 12 hr of dark) with
free access to water and standard rodent diet (Harlan Teklad 2018S). All mice
were fasted for 6 hr, starting at 8 AM, before experiments. Body composition
measurements were performed on awake mice using Bruker Mini-Spec
Analyzer (Bruker, TX). To examine the diet-induced changes in glucose and
fat metabolism, male VLCAD/, LCAD/, and WT mice were fed a regular
diet (TD2018; Harlan Teklad, Madison, WI) or HFD (55% fat by calories;Cell Metabolism 11, 402–411, May 5, 2010 ª2010 Elsevier Inc. 407-
-
,
f
f
-
]
)
t
,
f
-
.
-
rTD 93075; Harlan Teklad) ad libitum at the age of
17–18 weeks for 3 weeks, and metabolic parameters and
insulin action were measured. For glucose tolerance test,
1 g glucose/kg was introduced intraperitoneally for each
mouse, with blood samples collected at indicated time
intervals from the tail tips.
A comprehensive animal metabolic monitoring system
(CLAMS; Columbus Instruments, Columbus, OH) was
used to evaluate RQ and energy expenditure in mice after
3 weeks of high-fat pair feeding. Energy expenditure data
were normalized with respect to lean body weight. Energy
expenditure and RQ were calculated from the gas
exchange data (energy expenditure = [3.815 + 1.232 3
RQ]3 VO2). RQ is the ratio of VCO2 to VO2, which changes
depending on the energy source that the animal is using.
When carbohydrates are the only substrate being
oxidized, the RQ will be 1.0, and it will be 0.7 when only
fatty acids are oxidized. We studied five to eight male
mice per group. All procedures were approved by the
University of Alabama at Birmingham and the Yale Univer-
sity Animal Care and Use Committees.
Hyperinsulinemic-Euglycemic Clamp
At least 4 days before hyperinsulinemic-euglycemic clamp
experiments, mice were anesthetized with an intraperito-
neal injection of ketamine (100 mg/kg body weight) and
xylazine (10 mg/kg body weight), and an indwelling catheter was inserted in the left internal jugular vein. The catheters were external
ized through an incision in the skin flap behind the head, and the mice were
returned to individual cages after the surgery. To conduct experiments in
awake mice with minimal stress, a tail restraint method was used (Kim et al.
2000). A 120 min hyperinsulinemic-euglycemic clamp was conducted with
a prime continuous infusion of human insulin (Humulin, Eli Lilly) at a rate o
2.5 mU/kg/min (15 pmol/kg/min) to raise plasma insulin levels. Blood samples
(20 ml) were collected at 20 min intervals for the immediate measurement o
plasma glucose concentration, and 20% glucose was infused at variable rates
to maintain plasma glucose at basal concentrations. Insulin-stimulated whole
body glucose flux was estimated using a prime continuous infusion of [3-3H
glucose (10 mCi bolus, 0.1 mCi/min; NEN Life Science Products Inc.
throughout the clamps. All infusions were done using microdialysis pumps
(CMA/Microdialysis, North Chelmsford, MA). To estimate insulin-stimulated
glucose uptake and metabolism in individual tissues, 2-[14C]-deoxyglucose
(NEN Life Science Products Inc.) was administered as a bolus (10 mCi) a
75 min after the start of clamps. Blood samples (20 ml) were taken at 80, 85
90, 100, 110, and 120 min after the start of clamps for the determination o
plasma [3H]glucose, 3H2O, and 2-[
14C]-deoxyglucose concentrations. Addi
tional blood samples were obtained before the start and at the end of clamps
for measurement of plasma insulin and free fatty acid concentrations. At the
end of clamps, mice were anesthetized with sodium pentobarbital overdose
Within 5 min, four muscles (soleus, gastrocnemius, tibialis anterior, and quad
riceps) from both hind limbs, epididymal white adipose tissue, intrascapula
brown adipose tissue, and liver were taken. Each tissue, once exposed, was
Table 2. Gene Expression Relative to 18S in the Liver, Muscle, and Brown Adipose Tissue of High-Fat Diet-Fed WT and VLCAD/ Mice
Fed Liver Fasted Liver Muscle BAT
WT VLCAD/ WT VLCAD/ WT VLCAD/ WT VLCAD/
PPARa 126000 ± 19300 116000 ± 17600 344 ± 52 408 ± 47 5.8 ± 0.7 11 ± 1.4a 3420 ± 540 6250 ± 610a
PPARd 3360 ± 864 1670 ± 149 316 ± 16 351 ± 41 4.6 ± 0.5 4.1 ± 0.6 1360 ± 66 1810 ± 250
PPARg 2690 ± 357 2920 ± 249 3.2 ± 0.42 5.8 ± 0.98a 147 ± 29 125 ± 27 3280 ± 1290 2180 ± 548
MCAD 82100 ± 8560 92100 ± 1130 18200 ± 1780 52500 ± 1320a 149 ± 5 253 ± 32a 708000 ± 321000 432000 ± 64500
LCAD 317 ± 24 315 ± 34 294 ± 28 285 ± 48 208 ± 22 338 ± 42a 320000 ± 26300 448000 ± 47000a
CPT1 681 ± 63 644 ± 57 104000 ± 14600 158000 ± 27800 48 ± 2.6 55 ± 3.8 342 ± 160 273 ± 53
CPT2 39100 ± 5530 27000 ± 1260 5670 ± 497 10700 ± 1690a 18 ± 1.6 23 ± 1.6a 26300 ± 1630 26900 ± 1500
AOX 3593 ± 708 3789 ± 524 28 ± 3.3 30 ± 3.5 58900 ± 3630 73600 ± 7430a
PGC1a 6.3 ± 1.7 4.8 ± 0.5 1260 ± 200 1360 ± 160 41 ± 7.5 79 ± 25 64 ± 11 90 ± 15
PGC1b 3310 ± 345 3610 ± 980 7.5 ± 1.1 9.8 ± 1.2 10 ± 1.3 8.6 ± 1.0 40 ± 10 40 ± 5
SREBP1 3190 ± 670 2910 ± 460 31 ± 6 46 ± 7 40 ± 1.6 33 ± 2.2a 7000 ± 2330 3270 ± 487
CHREBP 69 ± 15 54 ± 10 54 ± 8.1 80 ± 13 860 ± 142 1020 ± 270 2930 ± 1090 4880 ± 1260
SCD1 1530000 ± 321000 494000 ± 108000a 5210 ± 1860 6340 ± 500 1550 ± 803 606 ± 136 3710000 ± 779000 1410000 ± 248000a
ACC1 1011 ± 125 1017 ± 213 36 ± 7 30 ± 3.6 2.6 ± 0.68 1.7 ± 0.13
ACC2 21700 ± 2300 16500 ± 4250 2.1 ± 1.0 1.2 ± 0.22 6.2 ± 0.64 5.7 ± 0.62 27900 ± 15000 14700 ± 3480
DGAT1 3310 ± 361 2220 ± 98a 1.0 ± 0.1 1.2 ± 0.14 227 ± 40 208 ± 40
DGAT2 216000 ± 19200 167000 ± 19000 94 ± 8.5 115 ± 6.6 7.2 ± 1.3 9.6 ± 1.7 0.24 ± 0.07 0.15 ± 0.03
LXRa 49700 ± 3480 42100 ± 2040 32 ± 2.3 31 ± 3.9 273 ± 26 299 ± 65 1220 ± 396 1970 ± 387
CYP7A1 163000 ± 19100 190000 ± 35400 11086 ± 2380 12350 ± 3650
FXR 25000 ± 1140 24800 ± 1410 24 ± 1.0 22 ± 3.2 45600 ± 14600 35300 ± 3080 2910 ± 374 2010 ± 175
ABCB11 103000 ± 7420 70300 ± 6570a 196 ± 17 217 ± 49 1.1 ± 0.3 2.4 ± 1.5 1.4 ± 0.3 2.6 ± 1.7
UCP1 324000 ± 28900 399000 ± 20400a
UCP2 0.22 ± 0.04 0.29 ± 0.05 0.52 ± 0.09 0.53 ± 0.13
UCP3 38 ± 8.9 53 ± 17 143 ± 26 90 ± 6.4
Gene expression relative to 18S (3108). Data represent mean ± SEM of five mice per group.
a p < 0.05 compared with wild-type controls.
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Figure 5. Schematic Summary of Increased Fatty
Acid Oxidation and Insulin Sensitivity in High-Fat
Diet-Fed VLCAD/ Mice
Wehypothesize that, due to the build-up of long-chain fatty
acids in the mouse VLCAD-deficient state with enzymatic
compensation provided by intact LCAD activity, there is
a stimulation of fatty acid oxidation via (1) direct activation
of AMPK and (2) stimulation of PPAR-a with the collective
downstream activation of mitochondrial fatty acid oxida-
tion. The net effect is a resistance in the VLCAD / mice
to the build-up of DAG and the insulin-resistant state found
in the high-fat diet-fed WT mice.
Cell Metabolism
VLCAD/ Mice Are Protected from Insulin Resistancedissected out within 2 s, frozen immediately using liquid N2-cooled aluminum
blocks, and stored at –70C for later analysis.
Calculations
Rates of basal endogenous glucose production and insulin-stimulated whole-
body glucose uptake were determined as the ratio of the [3H]glucose infusion
rate (disintegrations per minute [dpm]/min) to the specific activity of plasma
glucose (dpm/mmol) during the final 30 min of basal and clamp periods,
respectively. Endogenous glucose production during clamps was determined
by subtracting the glucose infusion rate from the whole-body glucose uptake
(Rossetti and Giaccari, 1990). Glucose uptake in individual tissues was calcu-
lated from plasma 2-[14C]-deoxyglucose profile, whichwas fitted with a double
exponential curve using MLAB (Civilized Software, Bethesda, MD) and tissue
2-deoxyglucose-6-phosphate content as described previously (Kim et al.,
1996).
Biochemical Assays
Plasma glucose concentrations during clamps were measured using 10 ml
plasma by a glucose oxidasemethod on a Beckman glucose analyzer II (Beck-
man Instruments Inc., Fullerton, CA), and plasma insulin concentrations were
measured by RIA using kits from Linco Research Inc. (St. Charles, MO).
Plasma fatty acid concentrations were determined using an acyl-CoA
oxidase-based colorimetric kit (Wako Chemicals USA Inc., Richmond, VA).
Fat absorption in the gut was measured according to Jandacek et al. (2004).
For the determination of plasma [3-3H]glucose and 2-[14C]-deoxyglucose
concentrations, plasma was deproteinized with ZnSO4 and Ba(OH)2, dried to
remove 3H2O, resuspended in water, and counted in scintillation fluid (Ultima
Gold; Packard Instrument Co., Meriden, CT) on dual channels for separation
of 3H and 14C. The plasma concentration of 3H2Owas determined by the differ-
ence between 3H counts without and with drying. For the determination of
tissue 2-[14C]-deoxyglucose-6-phosphate content, tissue samples were
homogenized, and the supernatants were subjected to an ion-exchange
column to separate 2-deoxyglucose-6-phosphate from 2-deoxyglucose, as
described previously (Kim et al., 2000). Skeletal muscle and liver triglyceride
concentrations were determined using triglyceride assay kit (Sigma Chemical
Co.) and a method adapted from Storlien et al. (1991). Long-chain acyl-CoA
and diacylglycerol concentrations in skeletal muscle and liver were measured
as previously described (Yu et al., 2002). Akt2 (Alessi et al., 1996), AMPK
(Reznick et al., 2007), and PKC3 (Samuel et al., 2004) assays were performed
as previously described. For in vitro tissue fatty acid oxidation analysis, the
liver, gastrocnemius muscle, and brown adipose tissue were removed from
anesthetized mice just prior to sacrifice. Approximately 115 mg of tissue
were immediately placed in 1 ml of homogenization buffer (250 mM sucrose,
1 mM EDTA, and 10 mM tris-HCl [pH 7.4]) on ice. After mincing with scissors,
the tissues were homogenized in a Kontes dual 21 glass homogenizer for 15
passes across 30 s at 800 RPMwith a motor-driven Teflon pestle. The homog-
enates were then flushed with 95% oxygen/5% CO2 for 15 min on ice. The
palmitate oxidation was then determined by adding 600 ul of the homogenate
to 2.65 ml of reaction mixture (100 mM sucrose, 10 mM Tris-HCl, 5 mM potas-
sium phosphate, 80mMpotassium chloride, 1mMmagnesium chloride, 2mM
L-carnitine, 0.1 mM malate, 2 mM ATP, 0.05 mM coenzyme A, 1 mM dithio-
threitol, 0.2 mM EDTA, 0.5 uCi 1-14C-Palmitate, and 0.3% bovine serum
albumin), sealing the flasks immediately with kontes rubber stoppers andClightly shaking the mixture for 60min in a 30Cwater bath. The CO2 in the reac-
tion mixture was then liberated by the addition 300 ul of 12MHCL and trapped
with whatman paper soaked with 300 ul of 2 M sodium hydroxide. The trapped
14CO2 was then measured by liquid scintillation counting using a Perkin Elmer
Tri-Carb 3100TR scintillation counter (Doh et al., 2005).
Quantitative RT-PCR-Based Gene Expression
RNA was isolated from tissues using a commercially available kit (QIAGEN
RNeasy Kit, QIAGEN Inc, Valencia, CA) in combination with DNase I treatment.
After 2 mg of total RNA were reverse transcribed (Stratagene, La Jolla, CA) with
random primers, quantitative PCR was performed with a DNA Engine Opticon
2 System (MJ Research, Boston, MA) using SYBR green QPCR dye kit (Stra-
tagene, La Jolla, CA). The following primers were used: PPARa, 50-GCAGC
TCGTACAGGTCATCA-30 (F) and 50-CTCTTCATCCCCAAGCGTAG-30 (R);
PPARd, 50-CTGAAGGGAAGGGGGTAGAG-30 (F) and 50-TTCCTGGTACTGGG
ATCTGC-30 (R); PPARg, 50-ATGCCAAAAATATCCCTGGTTTC-30 (F) and 50-G
GAGGCCAGCATGGTGTAGA-30 (R); MCAD, 50-GCATCAACATCGCAGAGA
AA-30 (F) and 50- CATTGTCCAAAAGCCAAACC-30 (R); LCAD, 50-GCATCAACA
TCGCAGAGAAA-30 (F) and 50-GGCTATGGCACCGATACACT-30 (R); CPT1a,
50-AACCCAGTGCCTTAACGATG-30 (F) and 50- GAACTGGTGGCCAATGAG
AT-30 (R); CPT1b, 50-TTGTGCAGATTGCCCTACAG-30 (F) and 50- GTCATGGC
TAGGCGGTACAT-30 (R); CPT2, 50-GAAGAAGCTGAGCCCTGATG-30 (F) and
50- GCCATGGTATTTGGAGCACT-30 (R); AOX, 50-AGCTCCGATCAGCCAGA
CAT-30 (F) and 50-TTCTTGAAACAGAGCCCAGAATG-30 (R); SREBP1, 50-CAG
CTCAGAGCCGTGGTGA-30 (F) and 50-TTGATAGAAGACCGGTAGCGC-30 (R);
CHREBP, 50-ACCTGTCTCCCCCTCAAACT-30 (F) and 50-TGTCTTCTGAAGCG
TGGTTG-30 (R); PGC1a, 50-ATGTGTCGCCTTCTTGCTCT-30 (F) and 50-ATC
TACTGCCTGGGGACCTT-30 (R); PGC1b, 50-AACCCAACCAGTCTCACAGG-30
(F) and 50-CTCCTAGGGGCCTTTGTTTC-30 (R); SCD1, 50-AGATCTCCAGTTCT
TACACGACCAC-30 (F) and 50- GACGGATGTCTTCTTCCAGGTG-30 (R); ACC1,
50-ATTGGGCACCCCAGAGCTA-30 (F) and 50- CCCGCTCCTTCAACTTGCT-30
(R); ACC2, 50-GGGCTCCCTGGATGACAAC-30 (F) and 50- TTCCGGGAGGA
GTTCTGGA-30 (R); DGAT1, 50-GTTCCGCCTCTGGGCATT-30 (F) and50-GAATC
GGCCCACAATCCA-30 (R); DGAT2, 50-ACTCTGGAGGTTGGCACCAT-30 (F)
and 50- GGGTGTGGCTCAGGAGGAT-30 (R); LXRa, 50-AGCGTCCATTCAG
AGCAAGT-30 (F) and 50- CCCTTCTCAGTCTGCTCCAC-30 (R); CYP7A1, 50-GG
TCCTCCAGCAGAGAGCTA-30 (F) and 50- TTGCTTAAGCTACGCGGAAT-30
(R); FXR, 50-AAAAGGGGATGAGCTGTGTG-30 (F) and 50- ACATCCCCATCT
CTCTGCAC-30 (R); ABCB11, 50-GGCTTGCTACAGATGCTTCC-30 (F) and
50- GCCAAAAAGGGGAAGAAGAC-30 (R); UCP1, 50-GGGCCCTTGTAAACAA
CAAA-30 (F) and 50- GTCGGTCCTTCCTTGGTGTA-30 (R); UCP2, 50-GTAGC
ACCCGACCTCTGAAG-30 (F) and 50- ATGGGTCGTGGAGACTTGAC-30 (R);
UCP3, 50-TGCTGAGATGGTGACCTACG-30 (F) and 50-GCGTTCATGTATCGG
GTCTT-30 (R); and 18S rRNA, 50-TTCCGATAACGAACGAGACTCT-30 (F) and
50-TGGCTGAACGCCACTTGTC-30 (R). Product specificity was verified by
running products on an agarose gel. Messenger RNA levels (DCT values),
normalized to 18S rRNA, were expressed using the comparative method. The
18S rRNA levels showed no statistical difference between genotypes.
Statistical Analysis
Data are expressed as means ± standard error (SE). The significance of the
differences in mean values between WT and VLCAD/ and LCAD/ mice
were evaluated by using the unpaired Student’s t test.ell Metabolism 11, 402–411, May 5, 2010 ª2010 Elsevier Inc. 409
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